How is Verquvo prescribed?

Verquvo is administered in conjunction with other heart failure therapies.

Before starting Verquvo, care should be taken to optimise volume status & diuretic therapy to stabilise patients after the decompensation event, particularly in patients with very high NT-proBNP levels (see section 5.1 of SmPC).

The recommended starting dose is 2.5 mg Verquvo once daily. The dose should be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.

If patients experience tolerability issues (symptomatic hypotension or systolic blood pressure [SBP] less than 90 mmHg), temporary down-titration or discontinuation of Verquvo is recommended (see section 4.4 of SmPC).

Treatment should not be initiated in patients with SBP <100 mmHg (see section 4.4 of SmPC).

Verquvo should be taken with food. For patients who are unable to swallow whole tablets, Verquvo may be crushed & mixed with water immediately before administration (see section 5.2 of SmPC).

Missed dose: If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose. Patients should not take two doses of Verquvo on the same day.

For full details on how to prescribe Verquvo please refer to the Summary of Product Characteristics (SmPC)
which can be found in the Resources section of this website or online at:
https://www.medicines.org.uk/emc/

product/12775/smpc

https://www.medicines.org.uk/emc/product/

12775/smpc Last accessed November 2022

NT-proBNP, N-terminal pro B-type natriuretic peptide;SmPC, summary of product characteristics; SBP, systolic blood pressure

For full details on how to prescribe vericiguat please refer to the Summary of Product Characteristics (SmPC)
which can be found in the Resources section of this website or online at:
https://www.medicines.org.uk/emc/product/12775/smpc

https://www.medicines.org.uk/emc/product/

12775/smpc Last accessed November 2022

Reference list:

Summary of Product Characteristics (SmPC) 10mg https://www.medicines.org.uk/emc/product/12775/smpc Summary of Product Characteristics (SmPC) 10mg https://www.medicines.org.uk/emc/product/12775/smpc Return to content
Summary of Product Characteristics (SmPC) 5mg https://www.medicines.org.uk/emc/product/12774/smpc Summary of Product Characteristics (SmPC) 5mg https://www.medicines.org.uk/emc/product/12774/smpc Return to content
Summary of Product Characteristics (SmPC) 2.5mg https://www.medicines.org.uk/emc/product/12773/smpc Summary of Product Characteristics (SmPC) 2.5mg https://www.medicines.org.uk/emc/product/12773/smpc Return to content

PP-VER-GB-0032 | November 2022

Full details on Adverse event reporting can be found at the bottom of the page

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

Verquvo is administered in conjunction with other heart failure therapies.

Before starting Verquvo, care should be taken to optimise volume status & diuretic therapy to stabilise patients after the decompensation event, particularly in patients with very high NT-proBNP levels (see section 5.1 of SmPC).

The recommended starting dose is 2.5 mg Verquvo once daily. The dose should be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.

If patients experience tolerability issues (symptomatic hypotension or systolic blood pressure [SBP] less than 90 mmHg), temporary down-titration or discontinuation of Verquvo is recommended (see section 4.4 of SmPC).

Treatment should not be initiated in patients with SBP <100 mmHg (see section 4.4 of SmPC).

Verquvo should be taken with food. For patients who are unable to swallow whole tablets, Verquvo may be crushed & mixed with water immediately before administration (see section 5.2 of SmPC).

Missed dose: If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose. Patients should not take two doses of Verquvo on the same day.

For full details on how to prescribe Verquvo please refer to the Summary of Product Characteristics (SmPC)
which can be found in the Resources section of this website or online at:
https://www.medicines.org.uk/emc/product/12775/smpc

Verquvo is administered in conjunction with other heart failure therapies.

Before starting Verquvo, care should be taken to optimise volume status & diuretic therapy to stabilise patients after the decompensation event, particularly in patients with very high NT-proBNP levels (see section 5.1 of SmPC).

The recommended starting dose is 2.5 mg Verquvo once daily. The dose should be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.

If patients experience tolerability issues (symptomatic hypotension or systolic blood pressure [SBP] less than 90 mmHg), temporary down-titration or discontinuation of Verquvo is recommended (see section 4.4 of SmPC).

Treatment should not be initiated in patients with SBP <100 mmHg (see section 4.4 of SmPC).

Verquvo should be taken with food. For patients who are unable to swallow whole tablets, Verquvo may be crushed & mixed with water immediately before administration (see section 5.2 of SmPC).

Missed dose: If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose. Patients should not take two doses of Verquvo on the same day.

For full details on how to prescribe Verquvo please refer to the Summary of Product Characteristics (SmPC)
which can be found in the Resources section of this website or online at:
https://www.medicines.org.uk/emc/

product/12775/smpc

Reference list:

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

“Verquvo is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy”

Verquvo is administered in conjunction with other heart failure therapies.

Before starting Verquvo, care should be taken to optimise volume status & diuretic therapy to stabilise patients after the decompensation event, particularly in patients with very high NT-proBNP levels (see section 5.1 of SmPC).

The recommended starting dose is 2.5 mg Verquvo once daily. The dose should be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.

If patients experience tolerability issues (symptomatic hypotension or systolic blood pressure [SBP] less than 90 mmHg), temporary down-titration or discontinuation of Verquvo is recommended (see section 4.4 of SmPC).

Treatment should not be initiated in patients with SBP <100 mmHg (see section 4.4 of SmPC).

Verquvo should be taken with food. For patients who are unable to swallow whole tablets, Verquvo may be crushed & mixed with water immediately before administration (see section 5.2 of SmPC).

Missed dose: If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose. Patients should not take two doses of Verquvo on the same day.

For full details on how to prescribe Verquvo please refer to the Summary of Product Characteristics (SmPC) which can be found in the Resources section of this website or online at: https://www.medicines.org.uk/emc/product/12775/smpc

Verquvo is administered in conjunction with other heart failure therapies.

Before starting Verquvo, care should be taken to optimise volume status & diuretic therapy to stabilise patients after the decompensation event, particularly in patients with very high NT-proBNP levels (see section 5.1 of SmPC).

The recommended starting dose is 2.5 mg Verquvo once daily. The dose should be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.

If patients experience tolerability issues (symptomatic hypotension or systolic blood pressure [SBP] less than 90 mmHg), temporary down-titration or discontinuation of Verquvo is recommended (see section 4.4 of SmPC).

Treatment should not be initiated in patients with SBP <100 mmHg (see section 4.4 of SmPC).

Verquvo should be taken with food. For patients who are unable to swallow whole tablets, Verquvo may be crushed & mixed with water immediately before administration (see section 5.2 of SmPC).

Missed dose: If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose. Patients should not take two doses of Verquvo on the same day.

For full details on how to prescribe Verquvo please refer to the Summary of Product Characteristics (SmPC) which can be found in the Resources section of this website or online at: https://www.medicines.org.uk/emc/

product/12775/smpc

Reference list:

For full details on how to prescribe Verquvo please refer to the Summary of Product Characteristics (SmPC)
which can be found in the Resources section of this website or online at:
https://www.medicines.org.uk/emc/product/12775/smpc

For full details on how to prescribe Verquvo please refer to the Summary of Product Characteristics (SmPC)
which can be found in the Resources section of this website or online at:
https://www.medicines.org.uk/emc/